RxDoctor Payments Data

Carol Karp, MD

Ophthalmology · Miami, FLNPI 1316962525

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $69,837 of the $84,392 with a category attached, or 82.8%. Glaukos Corporation accounts for 88.1% of it on its own, with 14 other manufacturers making up the rest. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$84,392in general payments, 2019–2025

Across 84 payments — averaging $1004.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$74K
  • Alcon$4K
  • Johnson & Johnson Surgical Vision, Inc.$3K
  • Immunogen, Inc.$1K
  • Boehringer Ingelheim International GmbH$650
  • Sun Pharmaceutical Industries Inc.$140
  • plus $845 from 9 others

What the payments were for

  • Consulting fees$69,83783%
  • Speaking & faculty fees$7,6949%
  • Travel & lodging$2,5543%
  • Food & beverage$4,3075%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,392 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida →

Medicare billing

Part B allowed, 2024
$20,184
Medicare patients
129
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine15$10,889
Prednisolone Acetate82$2,934
Latanoprost29$354
Doxycycline Hyclate11$188
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim22$154
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha13$138

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Miami

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →